Novel therapeutic option for orbital atypical lymphoid hyperplasia
Article first published online: 19 JUL 2010
© 2010 The Authors. Clinical and Experimental Ophthalmology © 2010 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 38, Issue 9, pages 892–894, December 2010
How to Cite
Talaulikar, D., Tridgell, D., Leong, D., Dahlstrom, J. E., Cherian, M., Prosser, I. and Sunderland, K. (2010), Novel therapeutic option for orbital atypical lymphoid hyperplasia. Clinical & Experimental Ophthalmology, 38: 892–894. doi: 10.1111/j.1442-9071.2010.02378.x
- Issue published online: 8 DEC 2010
- Article first published online: 19 JUL 2010
- Accepted manuscript online: 19 JUL 2010 12:00AM EST
- Received 30 September 2009; accepted 21 June 2010.
- lymphoproliferative disorder;
- pathology of lymphoid lesion
Ocular lymphoid tumours represent a spectrum of lymphoproliferative disease and can be subdivided into benign or reactive lymphoid hyperplasia, indeterminate or atypical lymphoid proliferations and malignant lymphoma. Treatment options include a wait and watch approach, systemic steroids, local radiotherapy or systemic chemotherapy. We describe a case of bilateral atypical lymphoid hyperplasia treated successfully with combination immunotherapy and radiotherapy. A 60-year-old lady presented with proptosis and left supra-orbital mass and was diagnosed to have bilateral atypical lymphoid hyperplasia. She had extensive extraocular facial infiltrates but no other sites of involvement on staging investigations. She was treated with eight doses of rituximab 375 mg/m2 at weekly intervals with a good partial response, followed by consolidative radiotherapy. Rituximab may be an effective treatment adjunct/alternative for patients with atypical lymphoid hyperplasia of the orbit, particularly where widespread lesions preclude the use of initial radiotherapy.